ArticlesSexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis
Introduction
Findings from four randomised trials have shown that oral antiretroviral pre-exposure prophylaxis is effective in protecting against HIV acquisition in diverse geographical and at-risk populations.1, 2, 3, 4 Evidence of the effectiveness of daily oral tenofovir-based pre-exposure prophylaxis in HIV prevention, and of coitally dependent tenofovir gel5 and antiretroviral treatment as prevention,6 has spurred optimism that the global HIV epidemic might be reversed. One important question for implementation of these prevention strategies after proof of effectiveness in trials is will they increase behavioural risk compensation, defined as individuals using known effective HIV prevention interventions engaging in increased sexual risk taking. A substantial increase in risky sexual behaviours by people using pre-exposure prophylaxis, and other HIV prevention strategies, could offset the HIV protective benefits7 and increase the risk of sexually transmitted infections (STIs). In clinical trials of pre-exposure prophylaxis, no significant differences in sexual behaviour between experimental and placebo groups were reported.1, 2, 3, 4, 8, 9, 10 However, because the comparison groups had equivalent uncertainty of treatment assignment and benefits of the study drug during the double-blind trial period, absence of risk compensation might not fully show sexual behaviour in the context of known pre-exposure prophylaxis efficacy.
In July, 2011, findings from the Partners PrEP Study,1 a randomised, double-blind, placebo-controlled trial of pre-exposure prophylaxis with daily oral tenofovir with or without emtricitabine among African heterosexual HIV uninfected members of serodiscordant couples, showed efficacy of pre-exposure prophylaxis for HIV prevention. Participants who had been assigned to the active pre-exposure prophylaxis groups continued in the study and were informed that they were receiving active pre-exposure prophylaxis and that this prevention strategy had been shown to reduce risk of HIV acquisition. HIV incidence in the placebo group during the study was 2% per year overall and 3% or more among subgroups with increased risk characteristics; assignment to pre-exposure prophylaxis resulted in a 67% (daily oral tenofovir) and 75% (emtricitabine and daily oral tenofovir) reduction in transmission risk, with a roughly 90% reduction in risk estimated for those adherent to pre-exposure prophylaxis. We examined sexual behaviours of individuals before and after July, 2011, to assess the potential risk compensation after they learnt about the effectiveness of pre-exposure prophylaxis for HIV prevention. We hypothesised that individuals using pre-exposure prophylaxis who were aware of its proven efficacy against HIV acquisition might increase sexual behavioural risks.
Section snippets
Partners PrEP Study
We undertook a longitudinal analysis of data from the Partners PrEP Study, which has been described previously (NCT00557245).1, 11 Briefly, between July, 2008, and November, 2010, 4747 HIV serodiscordant heterosexual couples were enrolled and followed up at nine research sites in Kenya and Uganda. Eligible HIV-uninfected participants were 18 years or older, sexually active, and had normal hepatic and renal function.
HIV-uninfected partners were randomly assigned (1:1:1) to daily oral tenofovir,
Results
Of 4747 HIV-uninfected participants enrolled and followed in the Partners PrEP Study, 3163 were initially randomly assigned to the clinical trial's active pre-exposure prophylaxis groups. Of these, 3024 were included in the present analysis; 139 were not included: 38 because they had seroconverted to HIV before July 13, 2011, and 101 because their final study visit (ie, completing the 36 months of follow-up or early withdrawal specified by the protocol) happened on or before July 13, 2011. At
Discussion
The transition from a double-blinded, placebo-controlled phase to one in which all participants were aware that they were receiving active, effective pre-exposure prophylaxis in the Partners PrEP Study provided a natural experiment to assess behavioural risk compensation in individuals receiving open-label pre-exposure prophylaxis for HIV prevention. Our data suggest that provision of pre-exposure prophylaxis as part of a comprehensive prevention package was not associated with substantial
References (27)
- et al.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet
(2013) - et al.
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
Lancet
(2010) - et al.
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
N Engl J Med
(2012) - et al.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
N Engl J Med
(2010) - et al.
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana
N Engl J Med
(2012) - et al.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
Science
(2010) - et al.
Prevention of HIV-1 infection with early antiretroviral therapy
N Engl J Med
(2011) - et al.
The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study
PLoS One
(2008) - et al.
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial
Sex Transm Dis
(2008) - et al.
Preexposure prophylaxis for HIV infection among African women
N Engl J Med
(2012)
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
PLoS One
Cited by (84)
PrEP uptake and HIV viral suppression when PrEP is integrated into Ugandan ART clinics for HIV-negative members of HIV-serodifferent couples: A stepped wedge cluster randomized trial
2022, eClinicalMedicineCitation Excerpt :Today, PrEP is available at 260 facilities in Uganda and >175,000 people have ever been initiated on PrEP as part of the national programs. Heterosexual HIV-serodifferent couples in Uganda – where one partner is living with HIV and the other is HIV-negative – have been integral to global efforts to understand HIV transmission and identify prevention modalities.3–7 In Uganda PrEP guidance, HIV-serodifferent couples are recognized as a group to link to PrEP services.
Patient perspectives of pharmacists prescribing HIV pre-exposure prophylaxis: A survey of patients receiving antiretroviral therapy
2021, Journal of the American Pharmacists AssociationCitation Excerpt :In 1 survey, pharmacists had similar concerns that PrEP would lead to riskier behavior (68%) and higher STI rates (65%).19 However, these fears have not proved to be founded in clinical trials of PrEP, which actually showed increased condom use and no differences in the rates of STIs.21-23 Nevertheless, the concerns raised by the patients in the present study emphasize that pharmacists prescribing PrEP will have a responsibility to their patients that extends beyond the provision of a prescription.
Evaluating family physicians’ willingness to prescribe PrEP
2020, Medecine et Maladies InfectieusesHealth Care Worker Perspectives of HIV Pre-exposure Prophylaxis Service Delivery in Central Uganda
2022, Frontiers in Public Health
- †
Members listed at end of paper